Factors that correlated with treatment-related benefit were collectively seen in the aforementioned clinical trials of anti-CTLA-4 or anti-PD-1/PD-L1 monotherapy, such as elevated expression of PD-L1 in tumor tissue, use in the chemotherapy-naïve setting, and increased TMB. This evidence concerns the gene CTLA4 and neoplasm.